Due to the disruption of intracellular adhesion and enhanced motility, the loss of claudin-1 is associated with tumor cell invasiveness, high recurrence status, and a shorter recurrence-free survival in breast cancer [10], oral squamous cell carcinoma [11], and gastric carcinoma patients [11]. Here, CLDN1 is linked to breast cancer.